Viracta Therapeutics (FRA:RYI) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics ROE % Adjusted to Book Value?

Viracta Therapeutics's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Viracta Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Viracta Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Viracta Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Viracta Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics ROE % Adjusted to Book Value Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

-316.33

-77.39

-74.40

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial														-87.58	-133.04	-33.06	-	-

Competitive Comparison of Viracta Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Viracta Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's ROE % Adjusted to Book Value falls into.

Viracta Therapeutics ROE % Adjusted to Book Value Calculation

Viracta Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-125.73%	/	1.69
	=	-74.40%

Viracta Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Viracta Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

VIRX:USA RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.